Sep 10, 2020 / 12:55PM GMT
Yigal Dov Nochomovitz - Citigroup Inc., Research Division - Director
Okay, great. So welcome, everyone, to the third day of the Citi Biopharma Conference. I'm Yigal Nochomovitz, one of the Biotech analysts. (Operator Instructions). So it's my great pleasure to have with me this morning, Samantha Du, the CEO of Zai Lab, one of the companies I cover.
Questions and Answers:
Yigal Dov Nochomovitz - Citigroup Inc., Research Division - DirectorAnd maybe as a starting point, Samantha, just to get everyone oriented, if you could give us a 3- or 4-minute overview of Zai Lab, just highlighting some of the key assets in the pipeline and where you stand with your commercial efforts for ZEJULA and Optune.
Ying Du - Zai Lab Limited - Founder, Chairman & CEO
Yes. Good morning, Yigal, and thank you for your opening remarks. Since our inception in 2014, we have executed our two-pronged strategy through both in-licensing of potentially best-in-class and first-in-class assets and investing in internal R&D efforts. Today,
Trustpilot
